Compare NUVL & AAON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | AAON |
|---|---|---|
| Founded | 2017 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.7B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | AAON |
|---|---|---|
| Price | $106.76 | $94.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $135.00 | $104.00 |
| AVG Volume (30 Days) | 537.1K | ★ 1.0M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 0.42% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.21 |
| Revenue | N/A | ★ $1,315,577,000.00 |
| Revenue This Year | N/A | $18.10 |
| Revenue Next Year | N/A | $12.34 |
| P/E Ratio | ★ N/A | $78.04 |
| Revenue Growth | N/A | ★ 8.77 |
| 52 Week Low | $55.54 | $62.00 |
| 52 Week High | $113.02 | $136.62 |
| Indicator | NUVL | AAON |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 63.56 |
| Support Level | $101.25 | $83.24 |
| Resistance Level | $113.02 | $97.65 |
| Average True Range (ATR) | 5.62 | 4.23 |
| MACD | 0.75 | 1.89 |
| Stochastic Oscillator | 67.48 | 85.60 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BASX. It generates the majority of its revenue from the AAON Oklahoma segment which engineers, manufactures, and sells, semi-custom, and custom HVAC systems, designs and manufactures control solutions, and sells retail parts to customers through retail part stores and online.